AE-941 (AEterna)

Curr Opin Investig Drugs. 2004 Jun;5(6):668-77.

Abstract

AEterna is developing AE-941, an angiogenesis inhibitor derived from the ultrafiltration of liquid shark cartilage, with matrix metalloprotease (MMP)-2, MMP-9 and vascular endothelial growth factor inhibitory properties, for the potential treatment of non-small-cell lung cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Lung Neoplasms
  • Tissue Extracts / chemistry
  • Tissue Extracts / pharmacology
  • Tissue Extracts / therapeutic use*

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • Tissue Extracts
  • shark cartilage extract